A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)

NCT ID: NCT06140342

Last Updated: 2023-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-01

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this pilot is to develop a mobile application that detects physiological measures of individuals with Alzheimer's disease and related dementias and triggers auto-play of personalized songs in a wearable device. The investigators will test the feasibility and acceptability of the app. This app may be an important tool to include in daily caregiving in a home setting by extending established benefits of music therapy for people with Alzheimer's disease and related dementias.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia Agitation Depressive Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Feasibility study of music-based mobile app

To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A person with ADRD exhibits neuropsychiatric symptoms of dementia such as agitation, restlessness, depressed mood, etc.
* Stability with or without psychotropic or anti-depressant medications
* Ability to hear with or without an assistive device


* Family or close friend caregiver of persons with dementia
* Must be able to read and write in basic English

Exclusion Criteria

* Inadequate hearing
* History of psychosis or other mental disorders other than depression
* Presence of substance or alcohol abuse
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pennsylvania

OTHER

Sponsor Role collaborator

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

Autotune Me LLC

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Autotune Me, LLC

Brooklyn, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kendra Ray, PhD, MBA, MPH

Role: CONTACT

347-636-7157

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kendra Ray, PhD, MPH, MBA

Role: primary

347-636-7157

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3P30AG073105-02

Identifier Type: NIH

Identifier Source: secondary_id

View Link

3-P30-AG-073105-02 SUPPLEMENT

Identifier Type: -

Identifier Source: org_study_id